This study evaluates the safety and efficacy of Ferrlecit® (ferric gluconate; a form of intravenous iron) or ferrous sulfate (a form of oral iron) in improving the response to epoetin alfa among anemic cancer patients receiving chemotherapy.

Inclusion Criteria:

• Diagnosis of nonmyeloid malignancy
• Moderate to severe anemia
• Adequate iron stores as measured by either TSAT or ferritin
• About to start cycle of chemotherapy
• Eligible for epoetin alfa therapy

Exclusion Criteria:

• Highly elevated TSAT or ferritin
• Recent transfusion, epoetin alfa, darbepoetin or intravenous iron
• Medical conditions that would confound the efficacy evaluation